Accord Company Profile

✉ Email this page to a colleague

ACCORD has one hundred and fifty-five approved drugs.

There are four US patents protecting ACCORD drugs. There are three tentative approvals on ACCORD drugs.

There are thirty-five patent family members on ACCORD drugs in eighteen countries and three hundred and eighty-seven supplementary protection certificates in eighteen countries.

International Patents:	35
US Patents:	4
Tradenames:	132
Ingredients:	129
NDAs:	155
Patent Litigation for Accord:	See patent lawsuits for Accord
PTAB Cases with Accord as petitioner:	See PTAB cases with Accord as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	CLOPIDOGREL BISULFATE	clopidogrel bisulfate	TABLET;ORAL	202925-001	Mar 27, 2013	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Accord Hlthcare	VILAZODONE HYDROCHLORIDE	vilazodone hydrochloride	TABLET;ORAL	208209-003	Apr 27, 2021	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Accord Hlthcare	QUETIAPINE FUMARATE	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	090681-004	Nov 1, 2016	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Accord	CAMCEVI KIT	leuprolide mesylate	EMULSION;SUBCUTANEOUS	211488-001	May 25, 2021		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Accord Hlthcare	EPLERENONE	eplerenone	TABLET;ORAL	206922-001	Jul 13, 2017	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Accord Hlthcare	TOPIRAMATE	topiramate	TABLET;ORAL	076311-003	Mar 27, 2009	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0521471	0390023-0	Sweden	⤷ Sign Up	PRODUCT NAME: ROSUVASTATIN
2316456	349 22-2017	Slovakia	⤷ Sign Up	PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330
0627406	2011020	Ireland	⤷ Sign Up	PRODUCT: GILENYA FINGOLIMOD AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF REGISTRATION NO/DATE: IRELAND EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011; FIRST REGISTRATION NO/DATE: EUROPEAN UNION EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011
0763039	SPC/GB08/025	United Kingdom	⤷ Sign Up	PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119
0477295	SPC/GB99/046	United Kingdom	⤷ Sign Up	PRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701
1746976	132017000076571	Italy	⤷ Sign Up	PRODUCT NAME: SALE SUCROSOFATO DI IRINOTECAN, COME IL SALE SUCROSOFATO DI IRINOTECAN IN UN LIPOSOMA PEGILATO(ONIVYDE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1130, 20161018
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.